Mon, Dec 22, 2014, 5:36 AM EST - U.S. Markets open in 3 hrs 54 mins

Recent

% | $
Quotes you view appear here for quick access.

Exact Sciences Corporation Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • solantey@sbcglobal.net solantey Apr 20, 2011 1:02 PM Flag

    RPC - BioMed's Garza - "Strong Presentation - Full Report On the Way"

    "Garza at BioMed Reports"

    As you know, we have been following the dramatic turn-around story involving Radient Pharmaceuticals (AMEX:RPC) very closely. One tabloid which published a number of reports, almost managed to single-handedly destroy the reputation of the company and is now being investigated on multiple fronts for their involvement in publishing misleading/false headlines which shaved millions of dollars off the company's market cap and caused trading on the stock to be momentarily halted.

    In addition, the company has decided to do battle with ambulance chaser law firms who based their cases (on behalf of investors) on the very reports published by a columnist at that tabloid.

    Based on several developments in play, we believe the full vindication of Radient is about to begin. As such we are issuing this news alert to our subscribers.

    The first step in the vindication process is the continued listing of the company on the NYSE Amex Exchange. As you may recall, the company received notice that they might not be eligible to continue trading on the exchange after an official there failed to acknowledge or account for a massive debt-to-equity exchange which the company completed earlier in the year. In addition, the same tabloid's articles caused officials at the exchange to question the validity of contractually based claims and relationships with the Mayo Clinic, who- in full collaboration with the company- was completing a validation study of the company's early cancer detection technology.

    We have stood 100% behind our coverage of the company and their turn-around story and now we believe there is very strong evidence to suggest that NYSE officials will, as expected, rule in favor of Radient in the days ahead. If the ruling is issued as expected, this will allow the company to continue trading on the big board exchange.

    While we do not issue price targets, we also agree with other analysts and experts who have been commenting and publishing reports about the company in recent weeks- stating that RPC shares will rise back above $2 levels. In fact, one very bullish analyst recently issued a near term price target of $3-$4. After careful examination of the company's projections he reports that "Radient's revenues in 2011 could reach $12 million and that RPC will report a modest profit."

    While this has always been a speculative trade for us, much of the risk in the investment should be erased when the company announces the AMEX decision and files official records of the payments due from their announced $10 million order from India. The validity of that Indian order was also called into question by the same tabloid reporter, who referred to Radient's investors as "retards" and "mentally challenged" on multiple occasions despite being asked for an apology by investors in the company.

    Calls and emails to editors and officials about whether the tabloid- a publicly traded entity themselves- officially stood by or approved of such actions have never been responded to. In addition, our own investigation into the matter proved that many of the allegations were not only ill-researched, but actually may have even been made up entirely.

    After arming themselves with a special investigator, multiple law firms and other officials, the company is said to be looking closely at the commentary and allegations issued not only by that tabloid, but also by another well known penny stock blogger and his business associate who also published and tweeted various defamatory statements about the company. We believe the company has taken the damage those individuals have caused to their reputation and business very seriously and that they will likely take legal action against those individuals.

    Stay tuned.

    The "vindication" of Radient Pharmaceuticals is set to begin.

 
EXAS
25.97-1.410(-5.15%)Dec 19 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.